Climb Bio (CLYM) Income from Continuing Operations (2020 - 2026)
Climb Bio (CLYM) reported Income from Continuing Operations of 13697000.0 for Q1 2026, up 33.93% on a YoY basis from 10226994.67 in Q1 2025, and up 21.6% quarter-over-quarter from 17470000.0 in Q4 2025.
Climb Bio (CLYM) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Climb Bio has reported Income from Continuing Operations for 7 years, with the latest figure at 13697000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 33.93% year-over-year to 13697000.0; the trailing twelve-month figure through Mar 2026 stood at 52526000.0 (up 43.49% YoY), and the FY2025 full-year result was 59560000.0, up 19.39% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 13697000.0, up from 17470000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1664000.0 in Q1 2024, with the low at 54887000.0 in Q2 2024.
- Historically, Income from Continuing Operations has averaged 13332058.82 across 5 years, with a median of 8947000.0 in 2024.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations soared 92.62% — and 2025, when it sank 1145.85%.
- Climb Bio's Income from Continuing Operations stood at 8794000.0 in 2022, then soared by 57.1% to 3773000.0 in 2023, then plunged by 122.37% to 8390000.0 in 2024, then slumped by 108.22% to 17470000.0 in 2025, then advanced by 21.6% to 13697000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 13697000.0 (Q1 2026), 17470000.0 (Q4 2025), and 12855000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Climb Bio | 774.84 Mn | 774.84 Mn | - | -13.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.70 Mn |
| Dec 31, 2025 | -17.47 Mn |
| Sep 30, 2025 | -12.86 Mn |
| Jun 30, 2025 | -8.50 Mn |
| Mar 31, 2025 | -20.73 Mn |
| Dec 31, 2024 | -8.39 Mn |
| Sep 30, 2024 | -8.95 Mn |
| Jun 30, 2024 | -54.89 Mn |
| Mar 31, 2024 | -1.66 Mn |
| Dec 31, 2023 | -3.77 Mn |
| Sep 30, 2023 | -3.74 Mn |
| Jun 30, 2023 | -5.60 Mn |
| Mar 31, 2023 | -22.54 Mn |
| Dec 31, 2022 | -8.79 Mn |
| Sep 30, 2022 | -8.37 Mn |
| Jun 30, 2022 | -13.55 Mn |
| Mar 31, 2022 | -13.13 Mn |
| Dec 31, 2021 | -10.70 Mn |
| Sep 30, 2021 | -9.38 Mn |
| Jun 30, 2021 | -8.71 Mn |